Valuation: Axonics, Inc.

Market Cap 3.63B 3.24B 3.01B 2.74B 5.17B 351B 5.2B 36.26B 14.18B 179B 13.62B 13.32B 574B P/E 2022
-48.9x
P/E 2023 -502x
Enterprise Value 3.31B 2.96B 2.75B 2.5B 4.72B 320B 4.74B 33.08B 12.94B 163B 12.43B 12.16B 524B EV / Sales 2022
10x
EV / Sales 2023 7.74x
Free-Float
99.8%
Yield 2022 *
-
Yield 2023 -
3 years 48.3
Extreme 48.3
71.05
5 years 38.41
Extreme 38.41
79.92
10 years 11.95
Extreme 11.95
79.92
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/10/2013
Director of Finance/CFO 41 02/10/2023
Chief Operating Officer 47 01/08/2018
Director TitleAgeSince
Director/Board Member 69 01/02/2018
Director/Board Member 74 08/04/2019
Date Insider Type Main position Quantity % Market Cap. Importance
15/11/24 Issuer sale

Executive/Senior Manager

59,355 0.1161%
15/11/24 Issuer sale

Responsable ventes & marketing

109,664 0.2145%
15/11/24 Issuer sale

Chief Technology Officer

63,237 0.1237%
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%-.--%-.--%+22.04% 3.63B
+1.13%+2.15%-25.29%+2.94% 172B
+0.83%+2.43%-8.31%+17.77% 113B
+0.13%+0.69%-25.09%+3.95% 106B
+2.34%+2.49%-47.36%-10.38% 75.31B
+0.78%+4.79%+3.10%+73.94% 61.8B
+0.12%+3.62%+12.66%+67.70% 52.93B
+0.55%+3.93%-2.82%-30.87% 50.05B
+0.95%-0.08%-17.61%+17.13% 40.81B
-0.36%-1.46%+23.55%+1.23% 31.74B
Average +0.72%+1.83%-8.72%+16.54% 70.82B
Weighted average by Cap. +0.83%+2.09%-15.23%+13.53%

Financials

2022 2023
Net sales 274M 244M 227M 207M 390M 26.48B 392M 2.74B 1.07B 13.48B 1.03B 1.01B 43.31B 366M 327M 304M 277M 522M 35.44B 525M 3.66B 1.43B 18.05B 1.38B 1.35B 57.98B
Net income -59.7M -53.3M -49.55M -45.12M -85.09M -5.77B -85.5M -597M -233M -2.94B -224M -219M -9.45B -6.09M -5.44M -5.05M -4.6M -8.68M -589M -8.72M -60.84M -23.8M -300M -22.86M -22.36M -963M
Net Debt -348M -311M -289M -263M -496M -33.67B -499M -3.48B -1.36B -17.15B -1.31B -1.28B -55.08B -317M -283M -263M -240M -452M -30.7B -455M -3.17B -1.24B -15.63B -1.19B -1.17B -50.22B
Projected Income Statement - Annual - Axonics, Inc.
Logo Axonics, Inc.
Axonics, Inc. is a medical technology company, which develops and commercializes products to treat adults with bladder and bowel dysfunction. The Company has designed and developed both rechargeable (R20) and recharge-free (F15) implantable sacral neuromodulation (SNM) systems, which deliver mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder (OAB), urinary retention (UR) and fecal incontinence (FI). The recharge-free implantable neurostimulator (INS) is approximately 10cc in volume, utilizes constant current stimulation, an easy-to-use, intuitive recharge-free patient remote control and other related accessories. It engineered its recharge-free sacral neuromodulation (SNM) system to deliver constant-current stimulation. Its SNM system includes an easy-to-use wireless patient remote control that does not require recharging or replacement batteries.
Employees
797
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. AXNX Stock